Edition:
India

BioDelivery Sciences International Inc (BDSI.OQ)

BDSI.OQ on NASDAQ Stock Exchange Capital Market

2.70USD
15 Dec 2017
Change (% chg)

$0.08 (+2.86%)
Prev Close
$2.62
Open
$2.60
Day's High
$2.85
Day's Low
$2.53
Volume
171,239
Avg. Vol
70,289
52-wk High
$3.60
52-wk Low
$1.58

Latest Key Developments (Source: Significant Developments)

BioDelivery Sciences Reacquires Onsolis From Collegium Pharmaceutical
Friday, 15 Dec 2017 

Dec 14 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES REACQUIRES ONSOLIS® FROM COLLEGIUM PHARMACEUTICAL.BIODELIVERY SCIENCES - GOT 90-DAY NOTICE FROM COLLEGIUM REGARDING TERMINATION OF LICENSE AND DEVELOPMENT AGREEMENT FOR ONSOLIS.BIODELIVERY SCIENCES INTERNATIONAL - TERMINATION OF AGREEMENT WILL BE EFFECTIVE ON MARCH 8, 2018.BIODELIVERY SCIENCES - COLLEGIUM TO TERMINATE LICENSE DUE TO ITS AGREEMENT TO COMMERCIALIZE NUCYNTA IMMEDIATE RELEASE, NUCYNTA ER.BIODELIVERY SCIENCES - "WE WILL BE ASSESSING OPTIONS FOR COMMERCIALIZING ONSOLIS".BIODELIVERY SCIENCES - DO NOT CURRENTLY BELIEVE RETURN OF ONSOLIS TO US WILL HAVE MATERIAL IMPACT ON BUSINESS.  Full Article

BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary
Monday, 27 Nov 2017 

Nov 27 (Reuters) - BioDelivery Sciences International Inc ::BIODELIVERY SCIENCES - ‍OHIO BUREAU OF WORKERS COMPENSATION APPROVED CHANGE TO ITS FORMULARY RESULTING IN FAVORABLE POSITIONING FOR BELBUCA, BUNAVAIL.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍BELBUCA WILL BE ADDED TO FORMULARY AS A TIER 1 LONG-ACTING OPIOID WITHOUT RESTRICTIONS​.BIODELIVERY SCIENCES INTERNATIONAL INC - ‍CHANGES TO FORMULARY WILL GO INTO EFFECT APRIL 1, 2018​.  Full Article

BioDelivery Sciences reports Q3 loss per share $0.21
Friday, 10 Nov 2017 

Nov 9 (Reuters) - BioDelivery Sciences International Inc :BioDelivery Sciences reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.21.Q3 revenue $11.3 million versus I/B/E/S view $9.4 million.Q3 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S.  Full Article

BioDelivery sciences announces patent litigation settlement agreement with Teva
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Biodelivery Sciences International Inc :BioDelivery Sciences announces patent litigation settlement agreement with Teva.BioDelivery Sciences International Inc - ‍other terms of agreement are confidential​.BioDelivery Sciences - ‍as part of settlement agreement, co has entered into a non-exclusive license agreement with Teva ​.BioDelivery Sciences International - ‍ entered into settlement agreement with Teva Pharmaceuticals USA, Actavis Laboratories Ut, Teva Pharmaceuticals Industries.BioDelivery Sciences International Inc - ‍as part of settlement agreement BDSI has entered into a non-exclusive license agreement with Teva​.BioDelivery Sciences - settlement agreement permits Teva to first begin selling its generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier under certain circumstances.BioDelivery Sciences International - ‍ settlement agreement resolves BDSI's BUNAVAIL patent litigation against Teva pending in United States district court​.BioDelivery Sciences - ‍agreement with Teva permits Teva to first begin selling generic version of BUNAVAIL in U.S. On July 23, 2028 or earlier​.  Full Article

BioDelivery Sciences Q4 loss per share $0.29
Friday, 17 Mar 2017 

Biodelivery Sciences International Inc : Biodelivery sciences provides corporate update and reports fourth quarter and full-year 2016 financial results . Q4 loss per share $0.29 . Q4 revenue $3.9 million versus i/b/e/s view $3.9 million . Q4 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S . Biodelivery sciences international inc - intend to evaluate an array of belbuca-related business and commercial partnership opportunities . Biodelivery sciences international inc - expect approval of belbuca in canada in first half of 2017 .Biodelivery sciences international inc- had cash and cash equivalents of approximately $32.0 million at december 31, 2016..  Full Article

Biodelivery Sciences Q2 loss per share $0.31
Tuesday, 9 Aug 2016 

Biodelivery Sciences International Inc : Q2 loss per share $0.31 . Q2 revenue view $3.4 million -- Thomson Reuters I/B/E/S . Biodelivery Sciences provides corporate update and reports second quarter 2016 financial results . Q2 revenue rose 189 percent to $5.0 million .Q2 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

BioDelivery Sciences, Collegium Pharma sign licensing deal for pain drug
Thursday, 12 May 2016 

Collegium Pharmaceutical Inc : Collegium pharmaceutical inc says collegium will be responsible for manufacturing, distribution, marketing and sales of onsolis in u.s. . Financial terms of agreement include $2.5 million upfront non-refundable payment, payable to bdsi within 30 days . Financial terms of agreement include up to $17 million in potential payments based on achievement of milestones . Collegium will be responsible for manufacturing, distribution, marketing and sales of onsolis in u.s . Financial terms of agreement include upper-teen percent royalties based on various annual u.s. Net sales thresholds .Biodelivery sciences and collegium pharmaceutical announce the signing of a licensing agreement for onsolis® in the u.s..  Full Article

Biodelivery Sciences posts Q1 loss of $0.36/share
Tuesday, 10 May 2016 

Biodelivery Sciences International Inc : Biodelivery Sciences provides corporate update and reports first quarter 2016 financial results . Q1 loss per share $0.36 . Q1 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S . Q1 revenue $3.0 million versus I/B/E/S view $3 million . IND filing of Buprenorphine 30 day injection for treatment of Opioid dependence and chronic pain anticipated in q3 2016 . Strategic initiatives implemented to better align BUNAVAIL expenses with revenue . Strategic initiatives implemented expected to result in savings of approximately $20 million through 2017 .Says initiatives extend cash runway to Q3 of 2017.  Full Article